Titre :

Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination

Auteur(s) :

Alidjinou, Enagnon Kazali [Auteur]
Laboratoire de virologie - ULR 3610
Demaret, Julie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Corroyer-Simovic, Bénédicte [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Vuotto, Fanny [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Miczek, Sophie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Labreuche, Julien [Auteur]
Service de Biostatistiques [CHRU Lille]
Goffard, Anne [Auteur]
Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
Trauet, Jacques [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Lupau, Daniela [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Dendooven, Arnaud [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Huvent-Grelle, Dominique [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Podvin, Juliette [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dreuil, Daniel [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Faure, Karine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Deplanque, Dominique [Auteur]
Centre d'Investigation Clinique - Innovation Technologique de Lille - CIC 1403 - CIC 9301 [CIC Lille]
Bocket, Laurence [Auteur]
Laboratoire de virologie - ULR 3610
Duhamel, Alain [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Sobaszek, Annie [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
Hober, Didier [Auteur]
Laboratoire de virologie - ULR 3610
Hisbergues, Michael [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Puisieux, Francois [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Autran, Brigitte [Auteur]
Centre d'Immunologie et des Maladies Infectieuses [CIMI]
Yazdanpanah, Yazdan [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Labalette, Myriam [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Lefevre, Guillaume [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Titre de la revue :

Clinical Microbiology and Infection

Nom court de la revue :

Clin Microbiol Infect

Numéro :

29

Pagination :

P258.e1-258.e4

Éditeur :

Elsevier for the European Society of Clinical Microbiology and Infectious Diseases

Date de publication :

2022-10-15

ISSN :

1198-743X

Mot(s)-clé(s) en anglais :

COVID-19
Neutralizing antibodies
Omicron
T cells

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objectives We investigated serum neutralizing activity against BA.1 and BA.2 Omicron sublineages and T cell response before and 3 months after administration of the booster vaccine in healthcare workers (HCWs). Methods HCWs ...
Lire la suite >Objectives We investigated serum neutralizing activity against BA.1 and BA.2 Omicron sublineages and T cell response before and 3 months after administration of the booster vaccine in healthcare workers (HCWs). Methods HCWs aged 18–65 years who were vaccinated and received booster doses of the BNT162b2 vaccine were included. Anti–SARS coronavirus 2 IgG levels and cellular response (through interferon γ ELISpot assay) were evaluated in all participants, and neutralizing antibodies against Delta, BA.1, and BA.2 were evaluated in participants with at least one follow-up visit 1 or 3 months after the administration of the booster dose. Results Among 118 HCWs who received the booster dose, 102 and 84 participants attended the 1-month and 3-month visits, respectively. Before the booster vaccine dose, a low serum neutralizing activity against Delta, BA.1, and BA.2 was detectable in only 39/102 (38.2%), 8/102 (7.8%), and 12/102 (11.8%) participants, respectively. At 3 months, neutralizing antibodies against Delta, BA.1, and BA.2 were detected in 84/84 (100%), 79/84 (94%), and 77/84 (92%) participants, respectively. Geometric mean titres of neutralizing antibodies against BA.1 and BA.2 were 2.2-fold and 2.8-fold reduced compared with those for Delta. From 1 to 3 months after the administration of the booster dose, participants with a recent history of SARS coronavirus 2 infection (n = 21/84) had persistent levels of S1 reactive specific T cells and neutralizing antibodies against Delta and BA.2 and 2.2-fold increase in neutralizing antibodies against BA.1 (p 0.014). Conversely, neutralizing antibody titres against Delta (2.5-fold decrease, p < 0.0001), BA.1 (1.5-fold, p 0.02), and BA.2 (2-fold, p < 0.0001) declined from 1 to 3 months after the administration of the booster dose in individuals without any recent infection. Discussion The booster vaccine dose provided significant and similar response against BA.1 and BA.2 Omicron sublineages; however, the immune response declined in the absence of recent infection.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille
Institut Pasteur de Lille

Collections :

• IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483

Date de dépôt :

2023-10-20T05:59:02Z
2024-02-22T18:37:28Z